US Patent

US9433371 — In-body device with virtual dipole signal amplification

Formulation · Assigned to Proteus Digital Health Inc · Expires 2029-09-15 · 3y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects an in-body device with virtual dipole signal amplification, such as implantable or ingestible devices, that emit a detectable signal upon contact with a target physiological site.

USPTO Abstract

Virtual dipole signal amplification for in-body devices, such as implantable and ingestible devices, is provided. Aspects of the in-body deployable antennas of the invention include antennas configured to go from a first configuration to a second configuration following placement in a living body, e.g., via ingestion or implantation. Embodiments of the in-body devices are configured to emit a detectable signal upon contact with a target physiological site. Also provided are methods of making and using the devices of the invention.

Drugs covered by this patent

Patent Metadata

Patent number
US9433371
Jurisdiction
US
Classification
Formulation
Expires
2029-09-15
Drug substance claim
No
Drug product claim
Yes
Assignee
Proteus Digital Health Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.